DNLI

Over the past six months, Denali's stock has been impacted by several key events. The FDA approval of AVLAYAH™ for Hunter Syndrome likely had a positive impact. Q1 2026 financial results showed a narrower-than-expected loss, but shares fell. Takeda's termination of the collaboration for DNL593 introduced uncertainty. Q4 and full-year 2025 financial results highlighted launch readiness for tividenofusp alfa. The clinical hold was lifted for DNL952, and a Phase 1b study was initiated for DNL628. Denali's stock increased by 18.8% between the beginning of 2026 and May 9, 2026.